BioLineRx: Investor Update & KOL Webinar: A Look at BioLineRx’s Development and Potential Commercialization of Motixafortide for Stem Cell Mobilization
|DATE:||September 28, 2022|
|TIME:||9:00 AM EDT|
About The Event
Join BioLineRx for an Investor Update and KOL Webinar featuring Dr. John F. DiPersio, Chief of the Division of Oncology, Washington University School of Medicine, St. Louis, and lead investigator of BioLineRx’s GENESIS Phase 3 clinical study, who will highlight the unmet need and current treatment landscape for the mobilization of stem cells (SCM) for multiple myeloma patients undergoing autologous stem cell transplantation.
A patient advocate will then moderate a panel discussion between an apheresis nurse, a multiple myeloma patient undergoing apheresis, and her caretaker to provide a detailed assessment of the current treatment experience.
BioLineRx recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking marketing approval for Motixafortide in SCM based upon the very successful GENESIS Phase 3 study. The GENESIS study, which compared Motixafortide to the current standard of care, G-CSF, met all primary and secondary endpoints with a very high level of statistical significance (p<0.0001).
Holly May, recently appointed President of BioLineRx USA, will then provide insight into the SCM market opportunity, as well as the Company’s launch and commercialization plans for Motixafortide in the U.S., if approved. CEO Philip Serlin will close with a recap of Motixafortide’s value proposition as well as opportunities for life cycle optimization.
A live Q&A session with the KOLs and management will follow the formal presentations.